Dow Down1.40% Nasdaq Down1.59%

Vertex Pharmaceuticals Incorporated (VRTX)

107.25 5.06(4.51%) Oct 1, 4:00PM EDT
ProfileGet Profile for:
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210
United States - Map
Phone: 617-341-6100

Index Membership:N/A
Full Time Employees:1,800

Business Summary 

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing other research and early-stage development programs. It markets KALYDECO to treat patients of six years of age and older with CF who have specific genetic mutations in their cystic fibrosis transmembrane conductance (CFTR) regulator gene in the United States, European Union, and Canada. The company also provides INCIVEK in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus infection, as well as markets telaprevir in other international markets. In addition, it is developing Ivacaftor in combination with CFTR corrector compounds, which has completed Phase III development program; and evaluating VX-661, a second investigational CFTR corrector, in combination with ivacaftor in Phase II clinical development. The company identifies and develops next-generation CFTR corrector compounds that evaluate in regimens combining ivacaftor with two CFTR corrector compounds. Further, it is involved in various other research and early-stage development programs, including programs in the areas of oncology, multiple sclerosis, and other serious and rare diseases. The company sells its products principally to major and selected regional wholesalers and specialty pharmacy providers in North America, as well as government-owned and supported customers in Europe. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Vertex Pharmaceuticals Incorporated

Corporate Governance 
Vertex Pharmaceuticals Incorporated’s ISS Governance QuickScore as of Oct 1, 2014 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 10; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Jeffrey M. Leiden M.D., Ph.D., 58
Chairman, Chief Exec. Officer and Pres
Dr. Joshua S. Boger Ph.D., 62
Founder, Exec. Director and Chairman of Science & Technology Committee
Mr. Ian F. Smith CPA, ACA, 48
Chief Financial Officer and Exec. VP
Dr. Peter R. Mueller Ph.D., 57
Chief Scientific Officer, Exec. VP of Global R&D and Member of The Scientific Advisory Board
Mr. Kenneth L. Horton , 47
Chief Legal Officer and Exec. VP
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders